Sort   by:  
 Page size 
TranscriptomicsRNA-Sequencing of vemurafenib-sensitive and resistant melanoma cell line SKMEL-239
RNA-seq data were generated for two conditions: for parental SK-MEL-239 cells grown in normal media and resistant SK-MEL-239 cells grown in media supplemented with vemurafenib.
ORGANISM(S): Homo sapiens 
2022-04-16 | E-MTAB-11609 | biostudies-arrayexpress
ProteomicsTRMU Confers Resistance of Melanoma Cells to Vemurafenib through Modulating Mitochondrial Electron Transport Chain Activities
Melanoma is the fifth most common newly diagnosed cancer in the U.S., where substitution of valine 600 with glutamic acid (V600E) in BRAF is the most frequently observed mutation in melanoma. Vemurafenib is an FDA-approved kinase inhibitor for BRAFV600E; while the drug can elicit effective remission...
ORGANISM(S): Homo sapiens (Human) 
2025-12-08 | PXD063781 | Pride
Vemurafenib resistance Mitochondrion Melanoma 
ModelsGiani2019 - Computational modeling to predict MAP3K8 effects as mediator of resistance to vemurafenib in thyroid cancer stem cells
Computational modeling to predict MAP3K8 effects as mediator of resistance to vemurafenib in thyroid cancer stem cells
2024-09-02 | BIOMD0000000883 | BioModels
TranscriptomicsType-1-cytokines synergize with oncogene inhibition to induce tumor growth arrest
Both targeted inhibition of oncogenic driver mutations and immune-based therapies show efficacy in treatment of patients with metastatic cancer but responses are either short-lived or incompletely effective. Oncogene inhibition can augment the efficacy of immune-based therapy but mechanisms by which...
ORGANISM(S): Mus musculus 
2015-02-20 | E-GEOD-62249 | biostudies-arrayexpress
GenomicsVemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
PRJNA862390 | ENA
ProteomicsProteins that directly interact with the full-length LINC01198, with EGFP as a control, in vemurafenib-resistant melanoma cells.
Using EGFP RNA as a control, the full-length LINC01198 pull-down was performed to identify proteins that directly interact with LINC01198 in vemurafenib-resistant melanoma cells.
ORGANISM(S): Homo sapiens (Human) 
2025-11-10 | PXD056757 | Pride
Vemurafenib resistence Linc01198 Melanoma Human 
TranscriptomicsExpression data from BRAFV600E A375 melanoma cells treated with vehicle or vemurafenib
Vemurafenib is a BRAF inhibitor with specificity for the most common BRAF mutant encountered in melanomas (BRAFV600E). Vemurafenib suppresses the proliferation of BRAF mutant human melanoma cells by suppressing downstream activation of the MEK/ERK mitogen activated protein kinases. We used microarra...
ORGANISM(S): Homo sapiens 
2014-05-20 | E-GEOD-42872 | biostudies-arrayexpress
ProteomicsEzrin inhibition overcomes acquired resistance to vemurafenib in BRAFV600E-mutated colon cancer and melanoma cells in vitro
In spite of the advancements in targeted therapy for BRAFV600E-mutated metastatic colorectal cancer (mCRC), the development of resistance to BRAFV600E inhibition limits the response rate and durability of the treatment. Better understanding of the resistance mechanisms to BRAF inhibitors will facili...
ORGANISM(S): Homo sapiens (Human) 
2023-08-29 | PXD042499 | Pride
Ezrin Brafv600e Actin cytoskeleton Nsc305787 Colon cancer Ezrin inhibitor Melanoma Braf inhibitor Vemurafenib 
TranscriptomicsRelief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas.
Analysis of transcriptome kinetics of SW1736 thyroid cancer cell line vs SK-MEL-28 melanoma cell line at various times after addition of 2 µM vemurafenib. The hypothesis tested was that SW1736 cells (vemurafenib-refractory) differentially express genes compared to SK-MEL-28 cells (vemurafenib sensit...
ORGANISM(S): Homo sapiens 
2013-02-01 | E-GEOD-37441 | biostudies-arrayexpress
ProteomicsThe secretome features associated with the development of re-sistance to vemurafenib in BRAFV600E mutated colon cancer cells
Patients with metastatic colorectal cancer (mCRC) carrying BRAFV600E mutation have worse response to chemotherapy and poor prognosis. The aim of this study was to conduct for the first time comparative proteomics profiling of the secretome from vemurafenib-sensitive vs. resistant colon cancer cells ...
ORGANISM(S): Homo sapiens (Human) 
2023-04-29 | PXD039766 | Pride
Brafv600e Braf inhibition Hspa5/ grp78 Colon cancer Rpa1 Er stress Vemurafenib Secretome Chemoresistance Dna replication Lc-ms/ms 
Sort   by:  
 Page size